Royal Bank of Canada Buys 26,790 Shares of LivaNova PLC (NASDAQ:LIVN)

Royal Bank of Canada increased its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 8.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 361,356 shares of the company's stock after acquiring an additional 26,790 shares during the period. Royal Bank of Canada owned about 0.67% of LivaNova worth $16,733,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. KBC Group NV increased its stake in shares of LivaNova by 130.5% during the fourth quarter. KBC Group NV now owns 99,928 shares of the company's stock worth $4,628,000 after purchasing an additional 56,580 shares during the period. PNC Financial Services Group Inc. increased its stake in LivaNova by 29.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock worth $292,000 after acquiring an additional 1,424 shares during the period. Rhumbline Advisers increased its stake in LivaNova by 0.5% during the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock worth $8,240,000 after acquiring an additional 899 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in LivaNova during the 4th quarter worth $2,772,000. Finally, Envestnet Asset Management Inc. increased its stake in LivaNova by 15.4% during the 4th quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock worth $2,034,000 after acquiring an additional 5,850 shares during the period. Institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Needham & Company LLC restated a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research note on Tuesday, May 13th. Stifel Nicolaus cut their price objective on LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Barclays cut their price objective on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a report on Thursday, May 8th. The Goldman Sachs Group cut their target price on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a report on Monday, March 3rd. Finally, Mizuho cut their target price on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $59.29.

LivaNova Stock Up 0.3%

LivaNova stock traded up $0.14 during midday trading on Thursday, reaching $42.93. The stock had a trading volume of 310,047 shares, compared to its average volume of 650,657. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $61.94. The company has a market capitalization of $2.34 billion, a P/E ratio of 102.26 and a beta of 0.84. The company has a fifty day moving average price of $38.93 and a two-hundred day moving average price of $44.47. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.